Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,372 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Standard of Care Clear all
Completed Phase 3 Interventional Results available

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT03391466
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
30
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

NCT04292730
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
1,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
106
States / cities
Anaheim, California • Berkeley, California • Burlingame, California + 76 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 4, 2026, 1:48 PM EDT
Terminated Phase 2 Interventional Results available

Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome

NCT02098993
View directory record Official record
Conditions
Acute Chest Syndrome, Sickle Cell Disease
Interventions
Unfractionated heparin
Drug
Lead sponsor
Craig Seaman
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 4, 2026, 1:48 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07192952
View directory record Official record
Conditions
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Interventions
Finerenone (Kerendia, BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 18 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
22
States / cities
Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Not applicable Interventional

Study Comparing the DOVER Silver Foley Catheter to a Standard of Care Catheter and a Marketed Silver Coated Foley Catheter

NCT00203515
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Standard Latex Foley Catheter, Silver Coated Latex Foley Catheter
Device
Lead sponsor
Tyco Healthcare Group
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 13, 2008 · Synced Sep 4, 2026, 1:48 PM EDT
Terminated Phase 3 Interventional Results available

Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment

NCT03052517
View directory record Official record
Conditions
Asthma
Interventions
QAW039 150 mg, QAW039 450 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
2,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
46
States / cities
Birmingham, Alabama • Encinitas, California • Newport Beach, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Sep 4, 2026, 1:48 PM EDT
Terminated Phase 1 Interventional

Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

NCT00089089
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
decitabine, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2013 · Synced Sep 4, 2026, 1:48 PM EDT
Recruiting Phase 4 Interventional

Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers

NCT06999590
View directory record Official record
Conditions
Pressure Ulcer, Ulcer, Ulcer, Pressure, Pressure Injury
Interventions
ACApatch™, caregraFT™, Standard of Care
Other
Lead sponsor
Tiger Biosciences, LLC.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

NCT01274182
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GP2013, MabThera, Rituxan
Biological
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
16
States / cities
Los Angeles, California • Lexington, Kentucky • Cumberland, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 4 Interventional Results available

Study of Oasis Ultra in Diabetic Foot Ulcers

NCT01835379
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Oasis, Standard
Device · Other
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
16
States / cities
Little Rock, Arkansas • Carlsbad, California • Fair Oaks, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Sep 4, 2026, 1:48 PM EDT
Terminated Phase 2 Interventional

Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis

NCT01268280
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Placebo, 250 mg CK-2017357, 500 mg CK-2017357
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
15
States / cities
Fresno, California • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 4, 2026, 1:48 PM EDT
Not listed Not applicable Interventional

A Prospective, Randomized, Comparative Study to Assess the Prevention of Surgical Site Infection (SSI's) in Revision Total Joint Arthroplasty Patients Treated With Single-Use Negative Pressure Wound Therapy (PICO) or Standard Care Dressings (AQUACEL Ag SURGICAL Dressing).

NCT03180346
View directory record Official record
Conditions
Surgical Incision
Interventions
PICO, Aquacel
Device
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 4, 2026, 1:48 PM EDT
Recruiting Not applicable Interventional

Healing, Equity, Advocacy and Respect for Mamas

NCT06273436
View directory record Official record
Conditions
Postpartum Complication
Interventions
H.E.A.R. for Mamas
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
16 Years to 49 Years · Female only
Enrollment
2,894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 1 Interventional Results available

A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available

NCT00785538
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
IMC-A12
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Scottsdale, Arizona • Detroit, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 4, 2026, 1:48 PM EDT
Recruiting Phase 2 Interventional

Antibiotic Tumescent For Chronic Wounds

NCT06327113
View directory record Official record
Conditions
Non-healing Wound
Interventions
CeFAZolin Injectable Solution
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 4, 2026, 1:48 PM EDT
Terminated Phase 2 Interventional Results available

Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19

NCT04479358
View directory record Official record
Conditions
COVID-19
Interventions
Tocilizumab, Standard of Care
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 4, 2026, 1:48 PM EDT
Completed No phase listed Observational

X-Ray Mammography Standard of Care Protocol

NCT01052740
View directory record Official record
Conditions
Breast Cancer, Invasive Carcinoma, In Situ Carcinoma, Fibrocystic Changes, Atypical Ductal Hyperplasia
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Not applicable Interventional Results available

Pelvic Floor Physical Therapy vs Standard Care in Transgender Women Undergoing Vaginoplasty for Gender Affirmation

NCT05690555
View directory record Official record
Conditions
Pelvic Floor Disorders
Interventions
Preoperative and Postoperative Pelvic Floor Physical Therapy (PFPT), No Pelvic Floor Physical Therapy (PFPT), Postoperative PFPT
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

NCT02234843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC)

NCT04793750
View directory record Official record
Conditions
HIV Infections, Syphilis
Interventions
Cepheid GeneXpert HIV-1 Qual POC HIV VL test, DPP HIV-Syphilis test system, OraQuick
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 2 Interventional

A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot)

NCT01154374
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
MEBO Wound Ointment, Standard of Care (sterile saline moistened gauze)
Drug · Procedure
Lead sponsor
Skingenix, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia

NCT00704353
View directory record Official record
Conditions
Anemia
Interventions
Ferric Carboxymaltose, Standard Medical Care (SMC)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 4, 2026, 1:48 PM EDT
Terminated Not applicable Interventional Results available

Clinical Trial of a Computer-driven Weaning System for Patients Requiring Mechanical Ventilation

NCT00606554
View directory record Official record
Conditions
Respiratory Insufficiency
Interventions
Computer-assisted weaning program, Standard of Care weaning
Device · Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)

NCT02668653
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia
Interventions
Chemotherapy, Quizartinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
11
States / cities
Gainesville, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 4, 2026, 1:48 PM EDT